Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

v3.24.3
Accrued Expenses and Other Current Liabilities
9 Months Ended
Sep. 30, 2024
Payables and Accruals [Abstract]  
Accrued Expenses and Other Current Liabilities

8. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands):

 

 

September 30, 2024

 

 

December 31, 2023

 

External research and preclinical development

 

$

9,984

 

 

$

8,001

 

Employee compensation and benefits

 

 

4,788

 

 

 

6,993

 

Professional fees

 

 

707

 

 

 

1,015

 

Facilities and other

 

 

683

 

 

 

137

 

Accrued expenses and other current liabilities

 

$

16,162

 

 

$

16,146